Key mantle cell lymphoma companies such as AbbVie, Adicet Bio ... Parsaclisib, Umbralisib, Ibrutinib, Edralbrutinib, Narazaciclib, Lucitanib, and others are under different phases of mantle ...
with AbbVie's share dipping in trading after the announcement. Launched in 2013, Imbruvica (ibrutinib) earned $548 million last year, with $492 million of that in the US where Pharmacyclics ...
Key mantle cell lymphoma companies such as AbbVie, Adicet Bio, InnoCare Pharma Inc., Guangzhou ... Parsaclisib, Umbralisib, Ibrutinib, Edralbrutinib, Narazaciclib, Lucitanib, and others are under ...
"Despite substantial improvements in outcomes in patients with chronic lymphocytic leukemia with novel targeted agents" -- i.e., Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib ...
Imbruvica is an important drug for AbbVie and is its biggest revenue producer ... because they have historically responded poorly to ibrutinib therapy. Despite the failure to meet the overall ...
HOUSTON — Bruton's tyrosine kinase inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib have revolutionized the ...
clinicaltrialsarena on MSN11d
Oncternal stock crashes by 60% as it lays off staff and scraps trialsOncternal is halting the development of two cancer candidates, ONCT-534 and ONCT-808, after disappointing trial results.
"It's not surprising to many of you that ibrutinib has been removed from the ... a long list of pharmaceutical companies, including AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, Genentech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback